Radicava ORS FDA Approval History
FDA Approved: Yes (First approved May 12, 2022)
Brand name: Radicava ORS
Generic name: edaravone
Dosage form: Oral Suspension
Company: Mitsubishi Tanabe Pharma Corporation
Treatment for: Amyotrophic Lateral Sclerosis
Radicava ORS is a free radical scavenger indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Development Timeline for Radicava ORS
| Date | Article |
|---|---|
| May 13, 2022 | Approval FDA Approves Radicava ORS (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.